Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.
We evaluated the role of the activated clotting time (ACT) and activated partial thromboplastin time (APTT), both currently available as bedside tests, for monitoring anticoagulation following bolus injection of 2500 or 5000 IU heparin in 21 patients undergoing neuroradiological procedures. APTT was measured using the CoaguChek Pro device compared to the laboratory standard measurement and ACT comparing CoaguChek Pro to Hemochron Celite and Kaolin. Statistical analysis was performed using Bablok-Passing regression. Despite heparin doses of 2500-5000 IU APTT measurements were out of range in 67% of patients using CoaguChek Pro and in 76.5% of patients using the laboratory measurement. ACT was reliably determined in all patients. The correlation between the different devices (CoaguChek Pro vs. Hemochron Celite r=0.69, Kaolin r=0.78) and assays (Hemochron Celite/Kaolin r=0.85) was good. ACT ranged from 141-417 s measured by CoaguChek Pro and 138-320 s measured by Hemochron Celite and 172-381 s using Hemochron Kaolin. These results indicate that ACT is the method of choice for monitoring anticoagulation in neuroangiographic procedures.
Kubalek
R
R
Department of Neurology, Academic Teaching Hospital Harlaching, Sanatoriumsplatz 2, 81545 Munich, Germany. rkubalek@web.de
Berlis
A
A
Schwab
M
M
Klisch
J
J
Schumacher
M
M
D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009485:Neuroradiography; D010314:Partial Thromboplastin Time; D011446:Prospective Studies; D015641:Radiography, Interventional; D014914:Whole Blood Coagulation Time
D006493:Heparin